within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03A_HormonalContraceptivesForSystemicUse.G03AA18_DrospirenoneAndEstetrol;
model DrospirenoneAndEstetrol 
   extends Pharmacolibrary.Drugs.ATC.G.G03AA18;

  annotation(Documentation(
    info ="<html><body><p>Drospirenone and estetrol is a combined oral contraceptive containing a progestin (drospirenone) and a natural estrogen (estetrol); it is used for the prevention of pregnancy in women of reproductive age. The product is approved in several countries and marketed primarily under trade names such as Nextstellis and Drovelis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters refer to healthy premenopausal women receiving daily oral doses of 14.2 mg estetrol and 3 mg drospirenone, based on available summary data and regulatory sources.</p><h4>References</h4><ol><li><p>Nelson, AL (2023). Drospirenone and estetrol: evaluation of a newly approved novel oral contraceptive. <i>Expert opinion on pharmacotherapy</i> 24(16) 1757–1764. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2023.2247979&quot;>10.1080/14656566.2023.2247979</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37691580/&quot;>https://pubmed.ncbi.nlm.nih.gov/37691580</a></p></li><li><p>Regidor, PA, et al., &amp; Mayr, M (2023). Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. <i>Women&#x27;s health (London, England)</i> 19 17455057221147388–None. DOI:<a href=&quot;https://doi.org/10.1177/17455057221147388&quot;>10.1177/17455057221147388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744531/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744531</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end DrospirenoneAndEstetrol;
